Orabloc (Articaine Hydrochloride, Epinephrine)

Articaine hydrochloride, the active ingredient in Orabloc, is a local anesthetic (amide) presented as a 4% w/v solution with epinephrine 1:200,000 for intraoral injection use. It provides rapid, profound anesthesia for dental extractions and other minor oral surgical procedures.

GNH USA supplies Orabloc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orabloc, containing articaine, provides local anesthesia for dental and oral surgical procedures.

Dental extractions: enables painless removal of teeth by numbing the target area. Restorative dental procedures: allows pain‑free drilling, filling and bonding. Periodontal surgery: anesthetizes gingival tissues for flap and graft work. Endodontic treatment: provides pulp anesthesia for root‑canal therapy. Other minor oral surgical procedures: facilitates anesthesia for biopsies, implant placement and similar interventions.

Common Side Effects: - Transient numbness or tingling in the injected area. - Mild swelling or bruising at the site. - Headache or dizziness. - Metallic taste in the mouth.

Serious or Rare Side Effects: - Allergic reaction or anaphylaxis. - Cardiovascular effects such as arrhythmia or hypertension due to epinephrine. - Central nervous system toxicity, including seizures. - Methemoglobinemia. - Prolonged or severe tissue necrosis.

Before using Orabloc, consider the following precautions.

Allergy assessment: confirm no known hypersensitivity to amide‑type local anesthetics. Cardiovascular evaluation: use caution in patients with hypertension or cardiac disease because of epinephrine. Dose minimisation: inject the smallest effective volume to reduce systemic exposure. Monitor for toxicity: watch for signs such as tinnitus, metallic taste, or altered consciousness. Store at room temperature: keep in the original container, protect from light and moisture.

Orabloc may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis with epinephrine. - Tricyclic antidepressants: increased central nervous system toxicity. - Beta‑blockers: may potentiate epinephrine‑induced cardiovascular effects.

Moderate Interactions (Monitor Closely): - Other amide local anesthetics: cumulative systemic toxicity. - Diuretics: may alter plasma protein binding, affecting drug levels. - Anticoagulants: may increase bleeding from the injection site.